VANCOUVER, Jan. 21 /PRNewswire-FirstCall/ -- Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI; TSX:ANP) today announced that shareholders of the Company approved all matters at its special shareholders meeting including a two-for-one stock split and a new stock option plan. Votes cast by shareholders represented over two thirds of the Company’s 41.6 million outstanding shares with over 99% in favor of the stock split and over 85% in favor of the new stock option plan. In light of receiving shareholder approval, regulatory approvals will be sought. The record date for the stock split is expected to be on or about February 3, 2004, and a mail out to shareholders of share certificates representing the additional shares will occur in the weeks following that date.
Angiotech Pharmaceuticals, Inc. is dedicated to enhancing the performance of medical devices and biomaterials through the innovative use of pharmacotherapeutics. To find out more about Angiotech Pharmaceuticals, Inc , visit our website at http://www.angiotech.com/.
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continue,” “estimate,” “expects,” “may” and “will” and words of similar import, constitute “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company’s filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.
Angiotech Pharmaceuticals, Inc.
CONTACT: Angiotech Pharmaceuticals Contact: Ian Harper (investors &media) ext. 6933; Rui Avelar (analysts) ext. 6996, Phone: (604) 221-7676